Breviscapine Emerges as Novel Therapeutic Strategy Against Diabetes-Aggravated Cancers

Investigators at Jiangsu Normal University in Jiangsu, People's Republic of China, have identified a novel "contextual programmed lethality" mechanism targeting the lactylation-ferroptosis axis in gastric cancer, highlighting the potential of the flavonoid breviscapine as a therapeutic strategy against diabetes-aggravated cancers. The research demonstrates that breviscapine inhibits diabetes-accelerated gastric cancer by dismantling lactylation-dependent GPX4 stabilization and co-opting restored cholesterol synthesis to fuel lethal lipid peroxidation.

Key Takeaways:

• The flavonoid breviscapine inhibits diabetes-accelerated gastric cancer through a novel 'contextual programmed lethality' mechanism targeting the lactylation-ferroptosis axis.
• Breviscapine targets EGFR and SRC within AGEs-RAGE-glycolytic networks, with molecular dynamics confirming stable high-affinity binding.
• The dual action of breviscapine selectively suppresses AGEs-driven malignancy, reducing proliferation by 63% and migration by 58%, while reversing Warburg metabolism.
• The efficacy of breviscapine is abrogated by LDHA overexpression or HMGCR inhibition, confirming mechanistic specificity.
• The research reveals that breviscapine exploits metabolic rewiring to induce iron-dependent death exclusively in diabetic microenvironments.
• The flavonoid emerges as a novel therapeutic strategy against diabetes-aggravated cancers, offering a promising approach for cancer treatment.

Statistics:

• 63 ± 5.2% reduction in proliferation by breviscapine.
• 58 ± 4.3% reduction in migration by breviscapine.
• 82 ± 7% reversal of Warburg metabolism by breviscapine.
• 3.2-fold increase in lipid peroxidation by breviscapine.
• 2.3-fold increase in cholesterol synthesis by breviscapine.

Sources:

• "Breviscapine targets EGFR and SRC to abrogate diabetes-driven GPX4 lactylation and ferroptosis resistance in gastric cancer" (Phytomedicine, 2025;148:157387)
• Jiangsu Normal University, Xuzhou, Jiangsu 221116, People's Republic of China.
• Elsevier Gmbh, Hackerbrucke 6, 80335 Munich, Germany (Publisher of Phytomedicine).